Marketwatch slrx
Web11 apr. 2024 · Salarius Pharmaceuticals (NASDAQ:SLRX) has a market capitalization of $3.53 million and generates $1.84 million in revenue each year. The company earns $ … Web13 jun. 2024 · Salarius Pharmaceuticals Inc. (NAS : SLRX) most recent headlines All News Headlines and Company Releases News Headlines for Salarius Pharmaceuticals Inc. …
Marketwatch slrx
Did you know?
WebGet the latest Salarius Pharmaceuticals Inc (SLRX) real-time quote, historical performance, charts, and other financial information to help you make more informed … Web28 okt. 2024 · This biotech drug developer is expected to post quarterly loss of $0.09 per share in its upcoming report, which represents a year-over-year change of +10%. Revenues are expected to be $0.6 million,...
WebBaudax Bio, Inc. (BXRX) Stock Price, News, Quote & History - Yahoo Finance Baudax Bio, Inc. (BXRX) NasdaqCM - NasdaqCM Delayed Price. Currency in USD Follow 2W 10W 9M 1.6000 -0.0200 (-1.23%) As... Web10 mrt. 2024 · According to the issued ratings of 1 analysts in the last year, the consensus rating for Salarius Pharmaceuticals stock is Buy based on the current 1 buy rating for SLRX. The average twelve-month price prediction for Salarius Pharmaceuticals is $100.00 with a high price target of $100.00 and a low price target of $100.00.
WebView the latest Salarius Pharmaceuticals Inc. (SLRX) stock price, news, historical charts, analyst ratings and financial information from WSJ. SLRX Salarius Pharmaceuticals … Web18 nov. 2024 · U.S. markets close in 2 hours 20 minutes Dow 30 +141.30 Nasdaq 12,059.04 -25.31(-0.21%) Russell 2000 +15.87(+0.90%) Crude Oil Gold (+0.78%) SNDL Inc. …
WebSLRX - Salarius Pharmaceuticals Inc. Chart, Quote and financial news from the leading provider and award-winning BigCharts.com.
WebSalarius Pharmaceuticals Inc. SEC filings breakout by MarketWatch. View the SLRX U.S. Securities and Exchange Commission reporting information. feel free to judgeWebSLRX is not currently paying a regular dividend. Latest Dividend N/A Ex-Dividend Date N/A Short Interest (01/31/23) Shares Sold Short 101,086 Change from Last 37.70% Percent of Float 5.20% Stock... feel free to keep using your pcWeb31 mrt. 2024 · (SLRX) Toevoegen aan lijst Rapport Geschatte financiële gegevens (e) Meer Financiële cijfers Bedrijfsprofiel Salarius Pharmaceuticals, Inc. is een biofarmaceutisch bedrijf in een klinische fase, dat zich richt op de ontwikkeling van effectieve behandelingen voor kankers met een grote, nog niet behandelde medische behoefte. feel free to learn appWebSalarius Pharmaceuticals Inc. company facts, information and financial ratios from MarketWatch. define circumscribing in a relationshipWeb19 mrt. 2024 · Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers … define city state greeceWeb13 jun. 2024 · SLRX - Salarius Pharmaceuticals Inc. Basic Chart, Quote and financial news from the leading provider and award-winning BigCharts.com. 1 day 2 days 5 days 10 … feel free to learn aptitudeWeb4 nov. 2024 · Salarius (SLRX) delivered earnings and revenue surprises of 11.11% and -100.00%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? define civic awareness